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ABSTRACT 56 
Background and aims: Treatment options for eosinophilic oesophagitis (EoE) patients 57 
include drugs (proton-pump inhibitors [PPI], swallowed topical corticosteroids [STC]), 58 
elimination diets, and dilation. Given the lack of data, we aimed to assess adult EoE patients’ 59 
satisfaction with different EoE-specific treatment modalities. 60 
Patients and methods: We evaluated therapy satisfaction recalled over a 12-month period 61 
using the validated “Treatment Satisfaction Questionnaire for Medication” (TSQM) that 62 
assesses effectiveness, side effects, convenience, and overall satisfaction. The score for 63 
each scale ranges from 0 (dissatisfied) to 100 (satisfied). To evaluate satisfaction with non-64 
pharmacologic therapies the questionnaire was modified and debriefed in three focus 65 
groups. The final questionnaire was sent to 148 patients. 66 
Results: Patient response rate was 74%. In the last 12 months, 24%, 75%, 19%, and 9% 67 
were treated with PPI, STC, elimination diet, and dilation, respectively. Patients identified the 68 
following considerations as important for therapy choice: effect on symptoms (89%), effect on 69 
oesophageal inflammation (76%), side effects (69%), and ease of use (58%). Patients found 70 
STC to be effective (83 points), convenient (83 points), and experienced no side-effects 71 
when using this therapy. When using STC alone (43%), overall patient satisfaction was high 72 
(86 points). Patients judged PPI to be most convenient (89 points), STC to be a bit less 73 
convenient (83 points), and diet to be most inconvenient (46 points) of three therapies 74 
examined. 75 
Conclusions: Adult EoE patients consider both therapy effect on symptoms and 76 
oesophageal inflammation as important criteria, when choosing EoE therapy, and appear to 77 
be satisfied with use of STC. 78 
Word count: 250 79 
Key words: eosinophilic oesophagitis, patient satisfaction, patient governance, shared 80 
decision-making 81 
82 
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INTRODUCTION 83 
Three types of therapies, namely drugs, diets, and dilation, are used to manage adult 84 
patients with eosinophilic oesophagitis (EoE).1,2 The drug-based therapy with most 85 
randomized placebo-controlled trials-generated evidence of efficacy in EoE is swallowed 86 
topical corticosteroids (STC) in a form of either syrup (budesonide diluted in sucralose 87 
solution), powder (obtained from blisters of fluticasone propionate inhaler discus or 88 
budesonide capsules), or spray (fluticasone propionate oral aerosol inhaler).1 STC are 89 
currently being used mostly off-label given that a formulation of budesonide developed 90 
specifically for adult EoE patients has only recently been approved by the European 91 
Medicines Agency (in 2017) and Swiss regulators (in 2018).3 Proton-pump inhibitors (PPI) 92 
are used in a subset of EoE patients responsive to this medication or else in those suffering 93 
from concomitant gastro-oesophageal reflux disease.1 Six-food (or less) elimination diet is a 94 
non-drug-based alternative for EoE management. Just like STC, the diet may lead to a 95 
reduction of oesophageal inflammation and symptomatic relief.1 Lastly, dilation of strictures 96 
often results in symptom relief that may be long-lasting; however, this measure does not 97 
affect the inflammatory activity of the disease.1 These therapy options are associated with 98 
either a risk of side effects, potential long-term sequelae associated with uncontrolled 99 
inflammation (dilation), or else need for a long-term avoidance of staple foods, such as milk, 100 
wheat and eggs (diet). As such, patients' perception of the efficacy and safety as well as life-101 
style preferences may profoundly influences the choice of EoE-specific therapy.102 
     To date, adult patients' satisfaction with various EoE-specific therapies has not been 103 
systematically assessed. The Treatment Satisfaction Questionnaire for Medication (TSQM) is 104 
a validated, general measure of patients' satisfaction with medication.4,5 We used the 105 
questions of the TSQM as well as those specifically developed for the purposes of this study 106 
to perform a questionnaire-based survey. In this prospective survey study, we aimed to 107 
evaluate the utilization of various EoE-specific therapies, assess adult patients’ satisfaction 108 
with the therapies they received in the last 12 months, and examine factors that are 109 
important for patients’ choice of therapy. 110 
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METHODS AND PATIENTS 111 
An overview of the key steps described in the methods section is shown in Figure 1. 112 
Study population 113 
Between September 2016 and November 2016, adult EoE patients (≥ 17 years of age) were 114 
recruited in 1 ambulatory care clinic in Switzerland as a part of the Swiss EoE Cohort Study 115 
(SEECS). The study was approved by ethic committee of canton Vaud (CER-VD, protocol 116 
number 148/15).6 Patients provided written informed consent for participation in the study. 117 
Disease diagnosis was established by investigators according to standardized criteria.1 118 
Patients with concomitant gastro-oesophageal reflux disease were also included. 119 
Development of the preliminary version of the study questionnaire 120 
We first created the questionnaire querying various demographic and disease-specific 121 
characteristics, utilization of various EoE-specific therapies and patients’ satisfaction with the 122 
therapies used in the last 12 months. 123 
     The initial questionnaire contained the following ten domains: socio-demographic 124 
characteristics (eight items), EoE-specific patient history (three items), presence of gastro-125 
oesophageal reflux (one item), presence of atopic diseases (four items), five items on past 126 
and present EoE-specific therapy (including PPI, STC, systemic corticosteroids, diets, and 127 
dilation), and factors that are important for patients’ choice of therapy (two items). In addition, 128 
the questionnaire contained validated items (questions) from TSQM that assesses treatment 129 
satisfaction with various therapies.4,5 Patients were asked to think of the satisfaction with 130 
various therapies, when looking back at the 12-months period. The TSQM was previously 131 
translated into German and underwent cultural adaption for Switzerland (TSQM version 1). 132 
The validated TSQM covers the most relevant aspects of the patients’ satisfaction with 133 
medication. The TSQM consists of 14 items falling into four scales: effectiveness (three 134 
items), side effects (five items), convenience (three items), and overall satisfaction (three 135 
items) (Supplementary Table 1).4,5 Unlike many other similar measures, the TSQM may 136 
also be used to compare various patient conditions and medication types. Treatment 137 
Satisfaction Questionnaire for Medication scale was used five times in the initial 138 
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questionnaire (including PPI, STC, systemic corticosteroids, diet, and dilation). The TSQM 139 
scale scores range from 0 (indicates lack of effectiveness) to 100 (indicates excellent 140 
effectiveness). 141 
Focus groups and individual patient interviews 142 
The focus group and individual patient interviews were conducted in accordance with ISPOR 143 
PRO Good Research Practices Task Force report.7,8 The purpose of the focus groups was to 144 
aid in the item generation phase of questionnaire development and ensure that “respondents 145 
understand how to complete the questionnaire, how to reference the correct recall period, the 146 
meaning of the items, how to use the response scales, and any other questionnaire features 147 
that may influence patient responses in the intended mode of administration.7,8 148 
     A board-certified psychologist (K.M., psychiatry clinic, University Hospital Basel) 149 
conducted two rounds of the cognitive interviews based on semi-structured interview guides 150 
that contained questions and probing strategies to assess patients’ understanding of 151 
questions/probing strategies were also used to assess appropriateness of recall period. 152 
Lastly, content coverage, format, and length of the entire questionnaire were assessed. Each 153 
focus group lasted approximately two hours. Two facilitators were also present during the 154 
focus groups discussions (D.H., and either A.M.S. or A.S.). D.H. conducted 4 individual face-155 
to-face semistructured interviews to find out, if last changes to the questionnaire had to be 156 
made. An individual patient interview lasted approximately 40 minutes. Focus groups/ 157 
individual patient interviews were recorded, translated from Swiss dialect of German (not a 158 
written language)into German, and transcribed. The research team reviewed transcriptions of 159 
the focus groups.  160 
     Forty-five and six EoE patients were approached during a routine clinical visit in the EoE 161 
clinic (Olten, Switzerland) and invited to participate in the focus groups and the face-to-face 162 
patient interviews, respectively. Thirty-three and two patients declined the invitation in the 163 
focus groups and the face-to-face patient interviews, respectively. Twelve EoE patients were 164 
interviewed during two focus groups (n = 6 for each focus group). Of the six patients with 165 
mean age of 38.5 years (range 26-51) participating in focus group number one, two were 166 
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female. Of the six patients with mean age of 47.3 years (range 34-63) participating in focus 167 
group number two, one was female. Four male patients with mean age of 59.5 years [range 168 
44-86] were individually interviewed.169 
We created semi-structured interview guides, which contained questions and probing170 
strategies to assess patients’ understanding of instructions, stem, response options and 171 
format of individual items. Depending on the item, questions/probing strategies were also 172 
used to assess appropriateness of recall period. Lastly, content coverage, format, and length 173 
of the entire questionnaire were assessed. 174 
Final questionnaire 175 
We created a cognitive summary report and an item tracking matrix documenting all the 176 
changes that were made, which included the following ones: 1) a single item assessing the 177 
presence of atopic diseases was separated into 5 items; 2) the part about treatment 178 
satisfaction with STC was expanded to include three different forms of application, namely 179 
syrup, powder, and spray, as one participant of the focus group took the STC in two different 180 
formulations and was satisfied with one form of application, but not with another; and 3) 181 
several items querying the use of concomitant therapies was introduced. 182 
     The final questionnaire (supplementary material) consisted of the following 11 domains: 183 
socio-demographic characteristics (7 items), EoE-specific patient history (3 items), presence 184 
of reflux (1 item), presence of atopic diseases (4 items), concomitant therapies (including 185 
antacids, H2-receptor antagonists, PPI, and corticosteroids - 7 items), 5 items on past and 186 
present EoE-specific therapy (including PPI, STC, systemic corticosteroids, diets, and 187 
dilation), and factors that are important for patients’ choice of therapy (2 items). The final 188 
questionnaire contains TSQM, which was used six times for assessment of satisfaction with 189 
PPI, STC (once per different application form - syrup, powder and spray), and dilation.4,5 The 190 
final questionnaire also included the items of Eosinophilic Esophagitis Activity Index patient-191 
reported outcomes (EEsAI PRO) questionnaire and adult EoE quality of life questionnaire 192 
(EoE-QoL-A).9,10 193 
Changes to Treatment Satisfaction Questionnaire for Medication 194 
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    TSQM was developed for pharmacologic treatments and used in its original form for PPI 195 
and STC. Given the fact that some patients took PPI and/or STC for many years, “I don’t 196 
remember” response option to item three of TSQM (“time until the drug started working”) was 197 
introduced. TSQM was adapted for diet and dilation, for which not all TSQM items were 198 
applicable (for diet, the item on ease of use related to formulation was removed; for dilation, 199 
the entire convenience scale was removed). The word “medication” was replaced with either 200 
“diet” or “dilation” and complementary verb. (For reviewers only: The summary of the 201 
changes is shown in Supplementary Table 2). 202 
Data handling and statistical analysis 203 
 We double entered the data into EpiData (version 3.1, Denmark) database, compared our 204 
entries, and extracted the data into Stata (version 13, USA). Data were fairly complete, as 205 
only two missing responses were found for the lead in items that inquired whether the patient 206 
took STC in the last 12 months, and no missing values were found for PPI, diets, and 207 
dilation. For all therapy types, no values for any of the TSQM items were missing. Descriptive 208 
results are presented as frequencies and percentages of the group total or median, 209 
interquartile range, and range. Multivariable logistic regression modelling was performed to 210 
evaluate the potential factors that might be associated with the outcome “assigning most 211 
importance to effects of therapy on symptoms and oesophageal inflammation as opposed to 212 
symptoms alone”. The following variables were entered into the model as independent 213 
variables: age, female gender, disease duration, history of oesophageal dilation, history of 214 
endoscopic disimpaction, education level (presence of university education or equivalent11), 215 
and anti-inflammatory therapy at time of study participation (either individually or more than 216 
one therapy). In a first step, the potential associated factors were tested separately. In a 217 
second step, all factors with a P-value < 0.15 were entered together into the multivariable 218 
logistic regression model. To assess the possibility of effect modification, we evaluated 219 
pairwise interaction terms of predictor variables. A p-value < 0.05 was considered statistically 220 
significant.221 
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RESULTS 222 
Patient characteristics 223 
     The final version of the questionnaire was sent by mail to 147 adults with EoE. The survey 224 
response rate was 74% (108/147). Patient and disease characteristics are shown in Table 1. 225 
Mean patient age was 46.9 (±5.3) years, 85/108 patients (79%) were male, and mean 226 
disease duration was 7.6 (±5.1) years. At inclusion, 45%, 75%, and 19% were treated with 227 
PPI, STC, and food elimination diet, respectively. In the past 12 months, 10 patients 228 
underwent oesophageal dilation. Thirty-five patients (32%) were managed with more than 229 
one therapy (28 patients [26%] with more than one anti-inflammatory therapy). Ten patients 230 
(9.3%) did not receive any treatment. 231 
Satisfaction with therapy 232 
    TSQM scales scores as well as average TSQM values for PPI, STC, and diet are shown in 233 
Table 2 (patients could be on more than one therapy in the past 12 months). When judging 234 
the convenience of using these EoE-specific therapies, patients found use of PPI being most 235 
convenient (score of 89). Although most patients needed to extract the steroid-powder 236 
containing blister from the diskus of asthma-specific medication, they found STC to be 237 
relatively convenient (score of 83). Patients on elimination diet found this therapy fairly 238 
inconvenient (score of 46). Patients did not observe any side-effects associated with the use 239 
of various EoE-specific therapies, which is consistent with their long-term use (especially PPI 240 
and STC, which were used for the duration of 6 and 5 years, respectively). 241 
     We also examined the therapy satisfaction in the population that used STC only (in a form 242 
of a powder), STC together with PPI, and STC together with elimination diets (Table 3). 243 
Patients found STC to be effective (score of 83), relatively convenient (score of 78), and 244 
experienced no side-effects when using this therapy. When using STC alone, overall 245 
satisfaction was fairly high (score of 86).  246 
Criteria important for the choice of therapy 247 
    The criteria that patients find important for the choice of therapy are shown in Table 4. The 248 
effect of therapy on symptoms (89%) and oesophageal inflammation (76%), possible side 249 
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effects (69%), and ease of therapy use (58%) were identified by patients as important 250 
considerations for the choice of therapy. When asked about the most important criterion for 251 
the choice of therapy (Figure 2), 45%, 32%, and 11% of patients chose the effect of 252 
treatment on symptoms and oesophageal inflammation, the effect of the treatment on the 253 
symptoms alone, and the effect of treatment on oesophageal inflammation alone, 254 
respectively, as deciding factor. 255 
     Step-wise logistic regression modelling was performed to identify factors associated with 256 
assigning most importance to improvement in symptoms and inflammation compared to that 257 
in symptoms alone as criteria for the choice of therapy (Table 5). In the univariable model, 258 
female gender, STC and PPI use at the time of the study were positively associated with 259 
putting greater emphasis on improvement in symptoms and oesophageal inflammation 260 
compared to that in symptoms alone, whereas presence of at least university degree (or 261 
equivalent) was negatively associated with this outcome. In the multivariable analysis, female 262 
gender (OR 3.727, 95%-CI 0.996-13.944, P-value=0.050), STC use at the time of the study 263 
(OR 3.760, 95%-CI 1.125-12.565, P-value=0.031), and PPI use at the time of the study (OR 264 
2.911, 95%-CI 0.869-9.754, P-value=0.083) were positively associated with the outcome. In 265 
the multivariable analysis, we observed a trend for negative association between presence of 266 
at least university degree (or equivalent) and the outcome (OR 0.406, 95%-CI 0.148-1.117, 267 
P-value=0.081). We also carried out the regression modelling, in which the use of more than 268 
one anti-inflammatory therapy at the time of the study (as opposed to each therapy 269 
individually) was examined. We found that use of more than one anti-inflammatory therapy is 270 
positively associated with putting greater emphasis on improvement in symptoms and 271 
oesophageal inflammation compared to that in symptoms alone in both univariable (OR 272 
6.544, 95%-CI 1.753-24.427, P-value=0.005) and multivariable analyses (OR 9.294, 95%-CI 273 
2.309-37.405, P-value=0.002 for more than one anti-inflammatory therapy; OR 3.874, 95%-274 
CI 1.061-14.152, P-value=0.040 for female gender; OR 0.385, 95%-CI 0.137-1.080, P-275 
value=0.070 for presence of at least university degree). 276 
277 
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DISCUSSION 278 
     This is the first study that examines adult EoE patients’ satisfaction with different 279 
therapies. We developed a survey to assess treatment satisfaction with EoE-specific therapy 280 
by consulting ISPOR guidelines and literature describing the use of TSQM as well as 281 
obtaining input from EoE patients by the means of focus groups and individual interviews. 282 
Patients with long-established EoE diagnosis appear to be satisfied with anti-inflammatory 283 
therapies, especially STC. We also found that effect of therapy on symptoms and 284 
oesophageal inflammation were important considerations for the choice of therapy in adults 285 
with EoE, and that female patients and those using anti-inflammatory therapies at the time of 286 
the study were more likely to assign greater importance to effect of therapy on both 287 
inflammation and symptoms as opposed to symptoms alone. 288 
     With an average TSQM score of 80, 85, 77 for PPI, STC and diet respectively, EoE 289 
patients appear to be satisfied with these EoE-specific therapies. Overall satisfaction scores 290 
as well as various TSQM scales scores are consistent with our current knowledge about 291 
these therapies. It is well known that whilst STC and diets appear to be efficacious/effective 292 
in the entire EoE patient population, PPI are only effective in a subset of EoE.12 Hence, the 293 
effectiveness scores are higher for both STC and diet when compared to PPI. Although high 294 
side-effects scales scores are indicative of lack of therapy-related side-effects, it is more 295 
likely that these patients have been diagnosed with EoE for a relatively long time and would 296 
have had time to switch the therapy in case of side-effects. It is also not surprising that, PPI 297 
that are administered in a form of a tablet received the highest convenience score when 298 
compared to STC blister that needs to be extracted from the fluticasone discus inhaler 299 
developed for asthma patients and diets adhering to which require patients to cook their own 300 
meals. Given that many of the patients take the pharmacologic therapies for an extended 301 
period of time (median treatment duration of 5 years or longer), it is only fitting that overall 302 
relatively high satisfaction scores are observed, as both PPI, STC, and diets have proven 303 
efficacy/effectiveness in patients with oesophageal eosinophilia.12-14 The overall satisfaction 304 
scores might have been different (and potentially lower), if therapy satisfaction would have 305 
Safroneeva et al. Adult patients’ satisfaction with EoE therapies P a g e  | 13 
been evaluated in newly-diagnosed patients needing to decide on the type of therapy that 306 
would work best for them and encountering side-effects of these therapies. 307 
     When asked about considerations that are important for the therapy choice, adult EoE 308 
patients consider both effect of medication on symptoms and oesophageal inflammation as 309 
important. The finding that from patients’ perspective therapy should target both inflammation 310 
and symptoms is consistent with the choice of endpoints for most recent trial testing short-311 
term efficacy of STC in adults with EoE for the purposes of regulatory approval.15 We found 312 
that female patients, those using single anti-inflammatory therapy, or a combination of those 313 
therapies at the time of the study were more likely to assign importance to effect of therapy 314 
on both symptoms and oesophageal inflammation as opposed to symptoms alone. Given 315 
that the majority of patients received a maintenance therapy of 0.25 mg of STC BID, a dose 316 
that brings only 16% of all patients into a complete remission, it is likely that disease activity 317 
in some of these patients on combination therapy was not adequately controlled.16,17 318 
     According to Atkinson et al. therapy satisfaction is a subset of overall patient satisfaction.4 319 
Besides therapy satisfaction, overall patient satisfaction covers all other “aspects of medical 320 
treatments, interpersonal aspects of clinical care, and processes of treatment”.4 Overall 321 
patient satisfaction interacts with the behaviour of patients as well as with the decision 322 
making. This relationship between overall patient satisfaction and patient’s behaviour is not 323 
considered to be strictly causal in nature, but rather an interaction between the domains that 324 
can influence each other. For example, overall patient satisfaction (and therapy satisfaction) 325 
can influence patient’s behaviour. We hypothesize that when an EoE patient is satisfied with 326 
the STC therapy (e.g. because of relative ease of use, effectiveness, or few side effects), it is 327 
more likely that this patient will pursue the treatment in a long-term run, even though most 328 
EoE symptoms would be gone following a short induction treatment. Given that EoE is a 329 
chronic disease, it is important for patients to adhere to anti-inflammatory treatment, as 330 
patients with an adequate disease control have fewer long-term complications, such as food 331 
bolus impactions.18 It is also possible for patient’s behaviour to influence therapy satisfaction. 332 
We hypothesize that an EoE patient, who is well-informed about advantages (e.g. no need 333 
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for medication) and disadvantages (e.g. may lead to lifestyle alterations) of dietary therapy 334 
for disease management is more likely to continue the therapy. As such, one could argue 335 
that minimizing the rates of therapy discontinuation through, among other things, better 336 
patient education might lead to a higher degree of satisfaction with EoE-specific therapy. 337 
     The results of this study should be interpreted with several considerations in mind. 338 
Although this is the first study that attempts to assess patients’ satisfaction with various EoE-339 
specific therapies, patients with long-established diagnosis from one gastroenterology 340 
practice specializing in management of this condition were recruited. It is likely that the high 341 
rates of therapy satisfaction might be a consequence of the following: 1) we ended up with a 342 
population of patients that used the therapies for a long time; and 2) it is likely that at least a 343 
proportion of patients, especially those participating in various clinical studies, were well 344 
informed about various aspects of this disease. As such, our results may not be 345 
generalizable to newly-diagnosed patients or those attending less-specialized 346 
gastroenterology practices. Whilst the patients’ satisfaction with PPI and STC could be 347 
evaluated using the original form of the questionnaire, the questionnaire had to be adapted 348 
for diet and dilation. Although minor word changes were performed, or else non-applicable 349 
items were removed entirely, satisfaction with diet has been queried using a non-validated 350 
form of this questionnaire, and the data obtained should be interpreted with caution. Although 351 
we used a validated TSQM, it is important to point out that validity of the overall 352 
questionnaire has not been rigorously assessed. This is especially true of the items querying 353 
the importance of the effects of therapy on various aspects of the disease, as these were not 354 
evaluated against another valid questionnaire or construct. The rate of dietary treatment 355 
observed in this study is lower (19%) than that observed in centers specializing in elimination 356 
diets (up to 57% in mixed adult and paediatric population).19 However, it is important to point 357 
out that the removal of inflammation-causing foods, such as milk- and wheat-based products, 358 
might pose challenges, as these foods represent important dietary staples of Swiss-German 359 
patients. Therefore, it is likely that, among other things, Swiss German patients’ dietary and 360 
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physician’s personal preferences contributed to high rates of STC use in the current 361 
population. 362 
     In conclusion, we found that patients with long-established EoE diagnosis appear to be 363 
satisfied with anti-inflammatory therapies, especially STC, and consider both symptoms and 364 
oesophageal inflammation as important targets for therapy.365 
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TABLES 366 
Table 1: Characteristics of the survey’s respondents. 367 
Characteristics (n=108) Frequency % 
Age at EoE diagnosis (years), mean ± SD 39.0± 15.6 NA 
Age at inclusion (years), mean ± SD 46.9± 15.3 NA 
Diagnostic delay (years), median (IQR), range 
2.3 (0.3 - 9.3), 0 – 
38.3 
NA 
Disease duration (years), mean ± SD 7.6 ± 5.1 NA 
Symptom severity as assessed by EEsAI PRO score§, 
median, (IQR), range 
12 (0 - 27), 0 - 65 NA 
EoE-specific quality of life as assessed by EoE-QoL-A§§, 
median, (IQR), range 
0.5 (0.29 – 0.96), 0 
– 1.83 
NA 
Male gender 85 78.7 










ISCED 2011 education levels 
- Level 3 







Experienced food bolus impaction that required 
endoscopic disimpaction (ever) 
39 36.1 
Gastrooesophageal reflux disease 
- Ever diagnosed 







Concomitant allergies (ever in life) 
- Asthma 
- Allergic rhinitis 
- Neurodermitis 
- Known food allergies 














- Swallowed topical corticosteroids (budesonide or 
fluticasone), ever 
- Swallowed topical corticosteroids at inclusion 
- Elimination diets, ever 
- Elimination diets at inclusion 
- Ooesophageal dilation, ever 

















Proton-pump inhibitor therapy 
- ever 







Abbreviations: EoE, eosinophilic oesophagitis; EEsAI PRO, eosinophilic oesophagitis activity index patient-reported outcome questionnaire; EoE-QoL-A, 368 
eosinophilic oesophagitis quality of life questionnaire for adults; IQR, interquartile range; NA, not applicable; SD, standard deviation; ISCED, international 369 
standard classification of education.21 370 
§The EEsAI PRO questionnaire assesses symptom severity in adults with EoE; score ranges from 0 (no symptoms) to 100 points (most severe symptoms) (7-371 
day recall period).19  372 
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§§The EoE-QoL-A questionnaire measures EoE-specific quality of life; score ranges from 0 points (perfect QoL) to 4 points (very bad QoL) (7-day recall 373 
period).20 374 
Table 2: Median TSQM scores and interquartile range. 375 
§For a side-effect scale, a score of 100 is given to patients, who do not experience side effects. 376 
Abbreviations: PPI, proton-pump inhibitor; STC, swallowed topical corticosteroids; TSQM, treatment satisfaction questionnaire 377 
for medication. 378 
379 
TSQM scales PPI (n = 27);  
median treatment 
duration 6 years [3 - 
9] 
STC (n = 83; median 
treatment duration 5 
years [2 - 6] 
Diet (n=21; 
median treatment 







66.7 [38.9 - 77.8] 
100.0 [100.0 – 100.0] 
88.9 [77.8 – 100.0] 
71.4 [50.0 -85.7] 
79.9 [70.3 – 85.5] 
83.3 [66.7 – 100.0] 
100.0 [100.0 – 100.0] 
83.3 [66.7 – 100.0] 
78.6 [64.3 – 92.9] 
84.8 [73.0 – 93.1] 
77.8 [50.0 – 88.9] 
100.0 [100 – 100.0] 
45.8 [33.3 – 66.7] 
78.6 [50.0 – 92.9] 
76.6 [59.8 – 81.9] 
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Table 3: Median TSQM scores and interquartile range for STC in a powdered form in 380 
patients with that therapy only as well as combined with either PPI or diets. 381 
§For a side-effect scale, a score of 100 is given to patients, who do not experience side effects. 382 
Abbreviations: PPI, proton-pump inhibitor; STC, swallowed topical corticosteroids; TSQM, treatment satisfaction questionnaire 383 
for medication. 384 
385 






83.3 [72.2 – 100.0] 
100 [100 – 100.0] 
77.8 [66.7 – 100.0] 
85.7 [64.3 – 92.9] 
77.8 [61.1 – 94.4] 
100.0 [87.5 – 100.0] 
83.3 [66.7 – 100.0] 
85.7 [57.1 – 96.4] 
83.3 [72.2 – 88.9] 
100 [100 – 100.0] 
94.4 [83.3 – 100.0] 
78.6 [71.4 – 85.7] 
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Table 4: Criteria important for the choice of therapy (n=108) 386 
 Frequency % 
Effect on symptoms 96 88.9 
Effect on inflammation in the oesophagus 82 75.9 
Potential side effects 75 69.4 
Ease of use 63 58.3 
Treating physician’s recommendation 54 50.0 
Compatibility with lifestyle 50 46.3 
Price 21 19.4 
Recommendation of other patients with this condition 12 11.1 
One’s own research (for example, on internet) 9 8.3 
Needs of the family 5 4.6 
Other Reasons 5 4.6 
387 
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Table 5: Univariable and multivariable logistic regression evaluating factors associated with 388 
assigning most importance to control of inflammation and symptoms (n=49) over control of 389 
symptoms alone (n=34). 390 
 Univariable Multivariable 
 OR 95%-CI P OR 95%-CI P 
Age (years) 0.996 0.967-1.025 0.793    
Female 3.636 1.093-12.098 0.035 3.727 0.996-13.944 0.050 
Disease duration 
(diagnosed) (years) 
1.042 0.949-1.144 0.389    
Dilation (ever) 0.922 0.360-2.363 0.866    
Disimpaction (ever) 0.809 0.319-2.049 0.655    
Education level 
(ISCED level ≤3 vs. 
level ≥6) 
0.390 0.156-0.971 0.043 0.406 0.148-1.117 0.081 
STC use at the time 
of the study 
2.451 0.863-6.963 0.092 3.760 1.125-12.565 0.031 
PPI use at the time 
of the study 
2.320 0.747-7.207 0.146 2.911 0.869-9.754 0.083 
Elimination diet at 
the time of the study 
0.989 0.335-2.922 0.984    
Abbreviations: ISCED, international standard classification of education; PPI, proton-pump inhibitors; STC, 391 
swallowed topical corticosteroids. 392 
393 
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FIGURES 394 
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SUPPLEMENTARY TABLES 432 
Supplementary Table 1: Domains and items of the Treatment Satisfaction Questionnaire for 433 
Medication. 434 
Subscale Items 
Effectiveness 1. Prevents or treats 
2. Relieves symptoms 
3. Time to start working 
Side effects 4. Presence of side effects 
5. Bothersome side effects 
6. Interference with physical 
function 
7. Interference with mental 
function 
8. Side effects impact on 
satisfaction 
Convenience 9. Easy to use 
10. Plan when to use 
11. Convenient to take 
Overall 
satisfaction 
12. Confident in benefits 
13. Good outweighs the bad 
14. All things into account 
435 
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Supplementary Table 2: Application of the TSQM for EoE-specific therapy. 436 
CONFIDENTIAL (the questionnaire is proprietary, for reviewers only) 437 













Prevention or treatment 
Wie zufrieden oder unzufrieden 
sind Sie damit, wie gut das 
Medikament zur Vorbeugung 
oder Behandlung Ihrer 
Erkrankung geeignet ist? 
Wie zufrieden oder 
unzufrieden sind Sie damit, 
wie gut die Diät zur 
Vorbeugung oder Behandlung 
Ihrer Erkrankung geeignet ist? 
Wie zufrieden oder 
unzufrieden sind Sie damit, 
wie gut die Dilatation zur 
Behandlung Ihrer 
Erkrankung geeignet ist? 
Symptom relief 
Wie zufrieden oder unzufrieden 
sind Sie damit, wie das 
Medikament Ihre Beschwerden 
lindert? 
Wie zufrieden oder 
unzufrieden sind Sie damit, 
wie die Diät Ihre 
Beschwerden lindert? 
Wie zufrieden oder 
unzufrieden sind Sie damit, 
wie die Dilatation Ihre 
Beschwerden lindert? 
Time to effect 
Wie zufrieden oder unzufrieden 
sind Sie damit, wie lange es 
dauert, bis das Medikament 
anfängt zu wirken? 
Wie zufrieden oder 
unzufrieden sind Sie damit, 
wie lange es dauerte, bis die 
Diät angefangen hat zu 
wirken? 
Wie zufrieden oder 
unzufrieden sind Sie damit, 
wie lange es dauerte, bis die 










Presence of side effects 
Verspüren Sie 
Nebenwirkungen, weil Sie 
dieses Medikament nehmen? 
Verspüren Sie 
Nebenwirkungen, weil Sie 




nach der Dilatation oder 
längerfristig? 
Bothersomeness of side effects 
Wie sehr machen Ihnen die 
Nebenwirkungen des 
Medikaments zu schaffen, das 
Sie zur Behandlung Ihrer 
Erkrankung nehmen? 
Wie sehr machen Ihnen die 
Nebenwirkungen der Diät zu 
schaffen, die Sie zur 
Behandlung Ihrer Erkrankung 
haben? 
Wie sehr machen Ihnen die 
Nebenwirkungen der 
Dilatation zu schaffen, die 
Sie zur Behandlung Ihrer 
Erkrankung erhielten? 
Interference with physical function 
Wie sehr beeinträchtigen die Nebenwirkungen Ihren körperlichen Gesundheitszustand und wie 
Sie im Alltag zurechtkommen (d.h. Ihre Kraft, Energie, usw.)? 
Interference with mental function 
Wie sehr wirken sich die Nebenwirkungen auf Ihren geistigen Zustand aus (d.h. auf die 
Fähigkeit, klar zu denken, wach zu bleiben, usw.)? 
Side effect impact on satisfaction 
Wie sehr haben sich 
Nebenwirkungen des 
Medikaments auf Ihre 
allgemeine Zufriedenheit mit 
dem Medikament ausgewirkt? 
Wie sehr haben sich 
Nebenwirkungen der Diät auf 
Ihre allgemeine Zufriedenheit 
ausgewirkt? 
Wie sehr haben sich 
Nebenwirkungen der 
Dilatation auf Ihre 
allgemeine Zufriedenheit 
ausgewirkt? 
Continued on the next page… 438 
439 
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CONFIDENTIAL (for reviewers only) 440 












Ease of use 
Wie einfach oder schwierig ist 
es, das Medikament in seiner 
derzeitigen Form zu nehmen? 
not applicable not applicable 
Planning for use of treatment 
Wie einfach oder schwierig ist 
es, zu planen, wann Sie das 
Medikament jeweils nehmen? 
Wie einfach oder schwierig ist 
es, die Menus zu planen? 
not applicable 
Convenience of taking medication 
Wie einfach und bequem ist 
es, das Medikament wie 
verschrieben einzunehmen? 
Wie einfach und bequem ist 


















Confidence in benefits of treatment 
Wie überzeugt sind Sie davon, 
dass es gut für Sie ist, dieses 
Medikament zu nehmen? 
Wie überzeugt sind Sie 
davon, dass es gut für Sie ist, 
diese Diät zu nehmen? 
Wie überzeugt sind Sie 
davon, dass es gut für Sie 
ist, eine Dilatation zu 
erhalten? 
Good outweighs the bad 
Wie sicher sind Sie sich, dass 
die guten Seiten des 
Medikaments gegenüber den 
schlechten Seiten überwiegen? 
Wie sicher sind Sie sich, dass 
die guten Seiten der Diät 
gegenüber den schlechten 
Seiten überwiegen? 
Wie sicher sind Sie sich, 
dass die guten Seiten der 
Dilatation gegenüber den 
schlechten Seiten 
überwiegen? 
All things taken into account 
Wie zufrieden oder unzufrieden 
sind Sie insgesamt gesehen 
mit diesem Medikament? 
Wie zufrieden oder 
unzufrieden sind Sie 
insgesamt gesehen mit der 
Diät? 
Wie zufrieden oder 
unzufrieden sind Sie 
insgesamt gesehen mit 
dieser Therapie? 
441 
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